Loader

Pathways

PathWhiz ID Pathway Meta Data

PW126448

Pw126448 View Pathway
drug action

Zalcitabine Action Pathway (New)

Homo sapiens
Zalcitabine is a dideoxynucleoside used to treat HIV. When HIV infects a cell, the virus first binds and fuses with the cell, releasing its nucleocapsid containing its RNA and reverse transcriptase into the cytosol of the cell. The reverse transcriptase converts the viral RNA into viral DNA in the cytosol. The viral DNA goes to the nucleus through the nuclear pore complex where it undergoes the process of transcription. The new viral RNA formed from transcription is transported back to the cytosol through the nuclear pore complex and translation occurs to produce viral proteins. These viral proteins are assembled and new HIV viruses bud from the cell. Zalcitabine (dideoxycytidine) enters the cell and is converted into dideoxycytidine monophosphate by deoxycytidine kinase. UMP-CMP kinase then converts dideoxycytidine monophosphate into dideoxycytidine diphosphate. Dideoxycytidine diphosphate is metabolized to dideoxycytidine triphosphate via nucleoside diphosphate kinase. Dideoxycytidine triphosphate is an analog of deoxycytidine-5'-triphosphate (dCTP). Dideoxycytidine triphosphate inhibits the activity of HIV-1 reverse transcriptase by competing with its substrate, dCTP and by incorporation into viral DNA. Dideoxycytidine triphosphate lacks the 3'-OH group which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, therefore, once dideoxycytidine triphosphate gets incorporated into DNA, this causes DNA chain termination, preventing the growth of viral DNA. Less viral proteins are therefore produced, and there is a reduction in new viruses being formed.

PW145043

Pw145043 View Pathway
drug action

Zalcitabine Drug Metabolism Action Pathway

Homo sapiens

PW176308

Pw176308 View Pathway
metabolic

Zalcitabine Predicted Metabolism Pathway

Homo sapiens
Metabolites of Zalcitabine are predicted with biotransformer.

PW128435

Pw128435 View Pathway
drug action

Zaleplon Action Pathway

Homo sapiens
Zaleplon, a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class, serves as a sedative used for the short-term treatment of insomnia in adults. Functioning within the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex, it shares certain pharmacological attributes with benzodiazepines despite its distinct chemical structure. Classified as a schedule IV drug in the United States, Zaleplon interacts with the CNS GABAA-receptor chloride ionophore complex at benzodiazepine (BZ) omega-1 (BZ1, ο1) receptors. Its mechanism of action involves subunit modulation of the GABABZ receptor chloride channel macromolecular complex, and it also selectively binds to the brain omega-1 receptor found on the alpha subunit of the GABA-A/chloride ion channel receptor complex, enhancing t-butyl-bicyclophosphorothionate (TBPS) binding. Zaleplon, distinctly separate from benzodiazepines and other hypnotic agents, effectively addresses short-term insomnia by interacting with these receptor systems.

PW145060

Pw145060 View Pathway
drug action

Zaleplon Drug Metabolism Action Pathway

Homo sapiens

PW176167

Pw176167 View Pathway
metabolic

Zaleplon Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Zaleplon are predicted with biotransformer.

PW127615

Pw127615 View Pathway
drug action

Zanamivir Action Pathway

Homo sapiens
Zanamivir, also known as Relenza, is an inhibitor of the viral neuraminidase protein. This antiviral is used to treat and prevent influenza A and B infections. By interacting with the neuraminidase, Zabamivir renders the influenza virus unable to escape its host cell. Neuraminidases are essential for the cleaving of the terminal sialic acids on the glycosylated HA during the virus budding to facilitate its release. In consequence, the virus will not be able to infect other cells. This molecule is available as an intravenous solution or as a powder for inhalation.

PW144675

Pw144675 View Pathway
drug action

Zanamivir Drug Metabolism Action Pathway

Homo sapiens

PW132540

Pw132540 View Pathway
metabolic

Zanubrutinib Drug Metabolism

Homo sapiens
Zanubrutinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zanubrutinib passes through the liver and is then excreted from the body mainly through the kidney.

PW146905

Pw146905 View Pathway
drug action

Zanubrutinib Drug Metabolism Action Pathway

Homo sapiens